AbbVie (ABBV)
(Delayed Data from NYSE)
$173.61 USD
+1.29 (0.75%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $173.95 +0.34 (0.20%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$173.61 USD
+1.29 (0.75%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $173.95 +0.34 (0.20%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Should Pacer US Cash Cows 100 ETF (COWZ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for COWZ
AbbVie (ABBV) Parkinson's Candidate Faces 2nd FDA Rejection
by Zacks Equity Research
AbbVie (ABBV) issues the second CRL for Parkinson's disease medicine, ABBV-951, based on some observations on inspection of one of its third-party manufacturing facilities.
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
AbbVie (ABBV) reachead $170.75 at the closing of the latest trading day, reflecting a -1.15% change compared to its last close.
Is Pacer US Cash Cows 100 ETF (COWZ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for COWZ
Here's Why You Should Consider Buying Alvotech (ALVO) Stock
by Zacks Equity Research
Here, we discuss some reasons why buying Alvotech (ALVO) stock now may turn out to be a prudent move.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
If You Invested $1000 in AbbVie a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
by Kinjel Shah
FDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Imfinzi.
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
by Zacks Equity Research
J&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Here's Why AbbVie (ABBV) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi is now approved for four indications across immune-mediated inflammatory diseases.
AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
In the closing of the recent trading day, AbbVie (ABBV) stood at $171.36, denoting a +0.99% change from the preceding trading day.
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
by Zacks Equity Research
Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
by Kinjel Shah
An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.
AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate
by Zacks Equity Research
AbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DHS
AbbVie (ABBV) Laps the Stock Market: Here's Why
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $170.46, moving +0.61% from the previous trading session.
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
by Kinjel Shah
Eli Lilly's (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Tagrisso.
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
by Zacks Equity Research
Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug
by Zacks Equity Research
The late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with relapsed/refractory multiple myeloma who have received at least two lines of prior therapy.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the most recent trading session, AbbVie (ABBV) closed at $160.19, indicating a -0.65% shift from the previous trading day.
AbbVie (ABBV) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
by Zacks Equity Research
AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.